OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: D. Watterson

5 Projects | 1 Researchers | $1,026,426 Invested

2016

Neurokine Therapeutics

D. Watterson, PhD

2016 Annual Goodes Prize for Excellence in Alzheimer's Drug Discovery: Catalyzing p38aMAPKI Drug Candidate, MW150, Into the Clinic

  • Funding Amount: $150,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Closed

2011

Northwestern University

D. Watterson, PhD

De-risking a novel kinase-targeted lead compound for future AD drug development

  • Funding Amount: $135,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2006

Northwestern University

D. Watterson, PhD

Gene-Regulating Protein Kinase Inhibitors as Potential AD Therapeutics

  • Funding Amount: $130,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2005

Northwestern University

D. Watterson, PhD

Novel Therapeutics Targeting Neuroinflammation

  • Funding Amount: $135,148
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2001

Northwestern University

D. Watterson, PhD

Ligands that Suppress Neuroinflammatory Responses

  • Funding Amount: $476,278
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed